Loading organizations...
Breaking is a biotechnology company based in Boston, Massachusetts, and Dallas, Texas, that develops naturally-derived biological solutions to degrade plastics in terrestrial and marine environments. The enterprise utilizes synthetic biology and engineered non-model organisms to address the global plastic pollution crisis while simultaneously targeting the reduction of carbon dioxide emissions generated from food waste. Gestated internally at Colossal Biosciences, the firm centers its core degradation technology on X-32, a flagship biological product originally discovered by researchers at Harvard University's Wyss Institute. Breaking has successfully secured $10.5 million in seed funding to scale its environmental waste management applications and commercialize its discoveries, with financial backing from venture capital investors including Builders VC. The organization was founded in 2022 by a team comprising Sukanya Punthambaker, Vaskar Gnyawali, George Church, Donald Ingber, Alba Tull, Kent Wakeford, and Ben Lamm.
Breaking has raised $11.0M across 1 funding round.
Breaking has raised $11.0M in total across 1 funding round.
Breaking has raised $11.0M in total across 1 funding round.
Breaking's investors include Builders VC, KdT Ventures, Wilbur-Ellis [Cavallo].
Breaking has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $11M Seed | — | Builders VC, KDT Ventures, Wilbur Ellis [cavallo] | Announced |
Breaking is a biotechnology startup developing bioinspired microorganisms to degrade plastic waste, addressing global plastic pollution by breaking down various plastics without pretreatment into harmless organic compounds and potentially valuable materials.[1][3] It serves environmental remediation efforts, industries generating plastic waste, and sustainability-focused sectors, solving the persistent problem of non-biodegradable plastics threatening ecosystems through a novel, nature-inspired genetic engineering approach.[1][3] Backed by prominent partners like Colossal Biosciences, the company shows early momentum via high-profile endorsements and affiliations with leading research institutions, positioning it as a spinoff innovator in plastic remediation.[1][3]
Breaking emerged from advancements in de-extinction and bioinspired engineering, spinning out of Colossal Biosciences—the world’s first de-extinction company—leveraging their genetic technologies for environmental applications.[1][3] The founding team includes biotech experts Sukanya Punthambaker, Ph.D., Vaskar Gnyawali, Ph.D., George Church, Ph.D. (Harvard genetics pioneer), Donald Ingber, M.D., Ph.D. (Wyss Institute), and business leaders Alba Tull, Kent Wakeford, and Ben Lamm.[3] The idea stemmed from discovering microorganisms that naturally digest plastic chemicals, enhanced by cutting-edge tech from collaborators like the Wyss Institute at Harvard, which focuses on bioinspired solutions for global challenges; early traction includes endorsements from investors like Builders VC, highlighting its breakthrough potential.[1][3]
Breaking rides the synthetic biology and climate tech wave, capitalizing on surging demand for biodegradable solutions amid escalating plastic pollution—over 400 million tons produced annually, with remediation markets projected to grow rapidly.[1][3] Timing aligns with global regulations like plastic bans and corporate sustainability mandates, amplified by AI-driven biotech tools from de-extinction leaders like Colossal, which spawn ecosystem innovations.[1][3] It influences the landscape by pioneering microbial engineering for waste, inspiring spinoffs in bio-manufacturing and circular economies, while Harvard/Wyss networks accelerate translation from lab to market, countering chemical recycling's limitations.[1][3]
Breaking is poised to scale its microbial tech through pilot deployments and partnerships, potentially disrupting a $100B+ plastics industry with commercial bioremediation products.[1][3] Trends like advancing CRISPR for non-model organisms and rising ESG investments will propel growth, evolving its role from plastic specialist to broader bio-degradation platform. As endorsements signal, this could redefine waste-to-value, breaking stereotypes in biotech and cementing its place among decade-defining climate breakthroughs—transforming planetary threats into opportunities.[1][3]
